RECURSION PHARMACEUTICALS-A (RXRX) Stock Overview
NASDAQ:RXRX - US75629V1044 - Common Stock
RXRX Key Statistics, Chart & Performance
The current stock price of RXRX is 4.7 USD. In the past month the price decreased by -11.15%. In the past year, price decreased by -28.46%.
RXRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.72B | ||
| AMGN | AMGEN INC | 12.84 | 150.72B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 143.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.4 | 101.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.19 | 58.99B | ||
| ARGX | ARGENX SE - ADR | 82.74 | 46.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.15 | 41.74B | ||
| INSM | INSMED INC | N/A | 31.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.54B | ||
| NTRA | NATERA INC | N/A | 24.21B | ||
| BIIB | BIOGEN INC | 8.97 | 21.05B |
Related stock screener links
About RXRX
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 840 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Company Info
RECURSION PHARMACEUTICALS-A
41S Rio Grande Street
Salt Lake City UTAH 84101 US
CEO: Christopher Gibson
Employees: 800
Phone: 13852690203
RECURSION PHARMACEUTICALS-A / RXRX FAQ
What is the stock price of RECURSION PHARMACEUTICALS-A today?
The current stock price of RXRX is 4.7 USD. The price increased by 1.62% in the last trading session.
What is the ticker symbol for RECURSION PHARMACEUTICALS-A stock?
The exchange symbol of RECURSION PHARMACEUTICALS-A is RXRX and it is listed on the Nasdaq exchange.
On which exchange is RXRX stock listed?
RXRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RECURSION PHARMACEUTICALS-A stock?
14 analysts have analysed RXRX and the average price target is 6.6 USD. This implies a price increase of 40.34% is expected in the next year compared to the current price of 4.7. Check the RECURSION PHARMACEUTICALS-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RECURSION PHARMACEUTICALS-A worth?
RECURSION PHARMACEUTICALS-A (RXRX) has a market capitalization of 2.04B USD. This makes RXRX a Mid Cap stock.
How many employees does RECURSION PHARMACEUTICALS-A have?
RECURSION PHARMACEUTICALS-A (RXRX) currently has 800 employees.
What are the support and resistance levels for RECURSION PHARMACEUTICALS-A (RXRX) stock?
RECURSION PHARMACEUTICALS-A (RXRX) has a support level at 4.54 and a resistance level at 4.7. Check the full technical report for a detailed analysis of RXRX support and resistance levels.
Is RECURSION PHARMACEUTICALS-A (RXRX) expected to grow?
The Revenue of RECURSION PHARMACEUTICALS-A (RXRX) is expected to grow by 1.18% in the next year. Check the estimates tab for more information on the RXRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RECURSION PHARMACEUTICALS-A (RXRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RXRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RXRX, evaluating the profitability, health, valuation and growth aspects
- RECURSION PHARMACEUTICALS-A (RXRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RECURSION PHARMACEUTICALS-A (RXRX) Sales and EPS estimates to see what analysts future expectations are.
- RECURSION PHARMACEUTICALS-A (RXRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RECURSION PHARMACEUTICALS-A (RXRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- RECURSION PHARMACEUTICALS-A (RXRX) Stock Chart to make your own analysis
- RECURSION PHARMACEUTICALS-A (RXRX) Latest news and press-releases to stay up to date.
Does RECURSION PHARMACEUTICALS-A (RXRX) stock pay dividends?
RXRX does not pay a dividend.
When does RECURSION PHARMACEUTICALS-A (RXRX) report earnings?
RECURSION PHARMACEUTICALS-A (RXRX) will report earnings on 2025-11-04, after the market close.
What is the Price/Earnings (PE) ratio of RECURSION PHARMACEUTICALS-A (RXRX)?
RECURSION PHARMACEUTICALS-A (RXRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).
What is the Short Interest ratio of RECURSION PHARMACEUTICALS-A (RXRX) stock?
The outstanding short interest for RECURSION PHARMACEUTICALS-A (RXRX) is 30.02% of its float. Check the ownership tab for more information on the RXRX short interest.
RXRX Technical Analysis
RXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RXRX. RXRX may be in some trouble as it scores bad on both profitability and health.
RXRX Financial Highlights
Over the last trailing twelve months RXRX reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -8.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.84% | ||
| ROE | -70.62% | ||
| Debt/Equity | 0.02 |
RXRX Forecast & Estimates
14 analysts have analysed RXRX and the average price target is 6.6 USD. This implies a price increase of 40.34% is expected in the next year compared to the current price of 4.7.
For the next year, analysts expect an EPS growth of 3.18% and a revenue growth 1.18% for RXRX